Taxanes in breast cancer: An update Journal Article
| Authors: | Conlin, A. K.; Seidman, A. D. |
| Article Title: | Taxanes in breast cancer: An update |
| Abstract: | Over the past decade the taxanes have proved to be fundamental in the treatment of breast cancer, Initially found to have efficacy in metastatic breast cancer, the taxanes are now vital components in the treatment of early-stage disease, in which their addition to adjuvant treatment of early breast cancer has been shown to improve overall survival. In addition, the taxanes have demonstrated a role in first-line therapy for metastatic disease, with some of the highest efficacy of any class of chemotherapy. Targeted therapies in combination with the taxanes have further improved survival for both early and metastatic disease. New formulations of taxanes may both improve antitumor activity and reduce toxicity. Copyright © 2007 by Current Medicine Group LLC. |
| Keywords: | cancer survival; overall survival; clinical trial; drug tolerability; fatigue; neutropenia; review; cancer recurrence; bevacizumab; cisplatin; doxorubicin; fluorouracil; sunitinib; dose response; drug dose comparison; drug efficacy; monotherapy; side effect; antineoplastic agents; capecitabine; gemcitabine; paclitaxel; adjuvant therapy; disease free survival; chemotherapy, adjuvant; neoadjuvant therapy; methotrexate; neurotoxicity; lymph node metastasis; gene overexpression; carboplatin; unindexed drug; infection; multiple cycle treatment; sensory neuropathy; breast cancer; gene amplification; bone marrow suppression; etoposide; blood toxicity; gastrointestinal symptom; heart disease; mucosa inflammation; neuropathy; stomatitis; peripheral neuropathy; epidermal growth factor receptor 2; drug dosage form comparison; cyclophosphamide; breast neoplasms; docetaxel; asthenia; drug fever; fever; axillary lymph node; survival time; cancer regression; disease severity; drug mechanism; add on therapy; systematic review; early cancer; dosage schedule comparison; cardiotoxicity; mitoxantrone; epirubicin; nanoparticle; taxoids; maximum plasma concentration; drug blood level; taxane derivative; anthracycline derivative; corticosteroid; trastuzumab; navelbine; recombinant granulocyte colony stimulating factor; dna topoisomerase (atp hydrolysing); drug treatment failure; hand foot syndrome; heart left ventricle ejection fraction; congestive heart failure; lapatinib; meta analysis; allergic reaction; hypersensitivity reaction; drug delivery system; granulocytopenia; cardiomyopathy; epothilone derivative; drug formulation; bridged compounds; cremophor; biricodar; paclitaxel tocosol |
| Journal Title: | Current Oncology Reports |
| Volume: | 9 |
| Issue: | 1 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2007-01-01 |
| Start Page: | 22 |
| End Page: | 30 |
| Language: | English |
| DOI: | 10.1007/bf02951422 |
| PUBMED: | 17164044 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 16" - "Export Date: 17 November 2011" - "CODEN: CORUA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work